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Background: Signs of disease progression (28%) and conversion to active treatment without evidence of 
disease progression (13%) are the main reasons for discontinuation of active surveillance (AS) in men with 
localised prostate cancer (PCa). We aimed to develop a nomogram to predict disease progression in these 
patients.
Methods: As a first step in the development of a nomogram, using data from Movembers’ GAP3 
Consortium (n=14,380), we assessed heterogeneity between centres in terms of risk of disease progression. 
We started with assessment of baseline hazards for disease progression based on grouping of centres 
according to follow-up protocols [high: yearly; intermediate: ~2 yearly; and low: at year 1, 4 & 7 (i.e., 
PRIAS)]. We conducted cause-specific random effect Cox proportional hazards regression to estimate risk of 
disease progression by centre in each group.
Results: Disease progression rates varied substantially between centres [median hazard ratio (MHR): 2.5]. 
After adjustment for various clinical factors (age, year of diagnosis, Gleason grade group, number of positive 
cores and PSA), substantial heterogeneity in disease progression remained between centres.
Conclusions: When combining worldwide data on AS, we noted unexplained differences of disease 
progression rate even after adjustment for various clinical factors. This suggests that when developing a 
global nomogram, local adjustments for differences in risk of disease progression and competing outcomes 
such as conversion to active treatment need to be considered.
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Introduction
Using data from the Movember GAP3 Consortium, the 
largest centralised prostate cancer (PCa) active surveillance 
(AS) database to date, we have previously shown that after 
5 years of follow-up, about 56.4% of men who started on 
AS were still on AS (1). We noted substantial variation by 
centre, but signs of disease progression (27.5% of men) and 
conversion to active treatment without evidence of disease 
progression (12.8% of men) were the main reasons for 
discontinuation.
A wide variety of predictive factors, including clinical 
and pathological factors, multi-parametric MRI (mpMRI) 
data, variability in biopsy timing, and nomograms are 
currently proposed for men with low-risk PCa on AS (2,3). 
For example, Wang et al. compared the Kattan, Steyerberg, 
Nakanishi and Chun nomograms to calculate the likelihood 
of indolent disease as well as various forms of progression 
in 273 patients meeting low-risk criteria who were managed 
by AS and who underwent multiple biopsies and/or delayed 
radical prostatectomy (4). Based on this fairly small sample 
size, it was concluded that existing nomograms have only 
modest accuracy in predicting the outcomes of patients 
undergoing AS.
Moreover, a recent national survey in the US evaluated 
the current use of prediction tools and nomograms for 
localised PCa based on clinical practice from radiation 
oncologists and urologist. A fifth of specialists reported not 
using any such tools in clinical practice, mainly due to the 
low use of AS for low-risk PCa (5). It is exactly for these 
reasons that the Movember Foundation launched its Global 
Action Plan Prostate Cancer Active Surveillance initiative 
(GAP3) in 2014. Its primary goal is to create a global 
consensus with uniform guidelines on the selection and 
monitoring of men with low-risk PCa (6).
Following the assessment of reasons for discontinuation, 
we now aimed to develop a nomogram to be used as a 
prediction tool for outcomes in men with localised PCa on 
AS. We present the following article in accordance with 




By combining patient data from established AS cohorts 
worldwide, the global GAP3 database was created 
between 2014 and 2016. In addition to ethical approval 
for sharing digital patient data in a centralized global 
database, inclusion criteria required an active registry of 
AS patients over the last 2 years or more, including at 
least ~50 patients annually. To date, 25 centres from the 
USA, Canada, Australasia, the UK and Europe fulfilled the 
requirements for participation and joined the initiative (6) 
resulting in data for a total of 15,101 men on AS (GAP3 
database v2.3.2). Each institution obtained institution 
ethical approval and signed a Movember End User License 
Agreement, Access Rights Principles Agreement, and the 
commonly agreed upon GAP3 analytical plan for the use of 
routinely collected anonymised clinical data. The study has 
conformed to the provisions of the Declaration of Helsinki 
(as revised in 2013). Details of ethical approval for each 
individual institution can be found in our cohort profile (6).
The AS inclusion criteria for the participating centres 
have been shown previously (1); despite the variation 
in protocols, most centres agreed that the most suitable 
patients for AS are those with age >18, pre-treatment 
clinical stage T1–T2, serum PSA ≤10 ng/mL, a biopsy 
Gleason grade group of 1 or 2, and a maximum of two 
tumour-positive biopsy core samples. An overview of 
contemporary worldwide AS practices across the world 
(and included in GAP3) can also be found in the systematic 
review by Kinsella et al. (7) and the cohort profile of the 
GAP3 database (8).
Apart from the inclusion criteria, there is also some 
variation in follow-up protocols. However, almost all 
protocols recommended serial measurements (with a 
variation in time-intervals) of serum PSA levels, digital 
rectal examination (DRE) and surveillance biopsy sampling 
in order to identify pathological progression. An overview 
of the AS follow-up protocols in GAP3 can be found in our 
previous publications (1,6). For the current analyses, we 
have grouped centres according to similarities in follow-up 
protocols (high, intermediate, and low)—the term “groups” 
in the results section hence refers to these different AS 
follow-up protocols. The high group includes those 
centres that performed a biopsy on an annual basis (Johns 
Hopkins, Atlanta, Lille, Singapore, Kagawa, UCSF, and 
MD Anderson), whereas the intermediate group includes 
those centres where the follow-up biopsy was taken about 
2 years after AS initiation (Memorial Sloan Kettering, 
Calgary, Baden, Cambridge, Valencia, MUSIC, Dublin, and 
Milan-PRIAS), and the low group refers to those centres 
that followed the PRIAS criteria, i.e., 1, 4, and 7 years 
after AS initiation (Erasmus, Vancouver, Helsinki, Malmo, 
Melbourne, and Toronto, and Milan-SAINT). Hence, a 
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total of 14,380 men were included in the analyses. The 
median age of the total population was 65 with IQR 60–70.
With respect to indicators of disease progression, we 
have previously (1) described that there is heterogeneity in 
recording across centres. We therefore used the following 
coding for defining signs of disease progression: ‘convert 
to watchful waiting’, ‘clinical progression’, ‘pathological 
progression’, ‘clinical and pathological progression’, ‘PSA 
progression (PSA-DT <3 years)’, ‘other PSA kinetics’, 
‘Patient choice/anxiety’, ‘doctors anxiety’, ‘radiological 
progression’, ‘died’, ‘lost to FU’, ‘other/unknown’ or ‘still 
on active surveillance’. If the reason for discontinuation of 
AS was classified as ‘other/unknown’ but the ‘pathological 
progression status’ was ‘Gleason grade group 3 or higher’ 
or the ‘clinical progression status’ was ‘cT3 or higher’ 
or ‘PSA progression status’ was ‘PSA >20’, the reason 
for discontinuation of AS was also categorised as signs 
of disease progression. Thus, similar to our previous 
publication (1), “disease progression” can refer to risk 
reclassification or disease progression as such and was used 
as the main outcome of interest in the current project. 
Conversion to active treatment, watchful waiting, or death 
were considered as competing risks.
Statistical methods
The main aim of the study was to create a nomogram to 
predict disease progression when on AS for PCa. First, 
we conducted cause-specific Cox proportional hazards 
regression to estimate the hazard ratio (HR) of disease 
progression and competing risks (watchful waiting, 
conversion to active treatment, or death) based on centre 
(i.e., exposure variable). The heterogeneity of prevalence of 
clinical factors and their relationship to disease progression 
was studied by dichotomising the clinical factors and 
modelling the univariable HRs of clinical factors by centre. 
Following the univariable analysis by centre, we then 
adjusted for age, year of diagnosis, Gleason grade group, 
number of positive cores, and PSA. Johns Hopkins was 
selected as the reference centre because it is one of the 
largest centres in the study and its patients characteristics 
are close to the average.
To further investigate heterogeneity in baseline 
upgrading risk between centres we estimated Cox frailty 
models. These frailty models include a random effect term 
for centre and the difference in upgrading risk between 
centres is parameterized using the variance of the frailty 
term. To aid the interpretation of the results we transformed 
the variance term to the median hazard ratio (MHR) (9). 
The MHR can be interpreted as the MHR of disease 
progression when moving a patient from a randomly chosen 
centre to a randomly chosen centre with a higher disease 
progression risk (Or comparing a patient with the same 
characteristics between two randomly chosen centres). We 
calculated the MHR using a frailty model not including any 
patient and tumour characteristics and investigated whether 
differences in included patients could partially explain the 
observed heterogeneity by adjusting for characteristics 
included in the previous analyses.
All statistical analyses were performed in R. Statistical 
codes are available upon request.
Results
Tables 1-3 show reasons for AS discontinuation the three 
groups of centres based on their study protocol for 
follow-up. In the centres that performed a biopsy on an 
annual basis (Table 1) and the centres that followed the 
PRIAS criteria (Table 3), the majority of patients in most 
of the centres discontinued due to treatment for disease 
progression. In the centres where the follow-up biopsy was 
taken more than a year after AS initiation (Table 2), the main 
reason for discontinuation was either treatment for disease 
progression or conversion to watchful waiting or active 
treatment (without evidence of progression).
We performed univariable heterogeneity analysis for 
disease progression whilst considering all other reasons for 
discontinuation as censoring events. Figure 1 illustrates this 
graphically by showing the distribution of HRs for both 
conversion to active treatment as well as progression. In 
each group, there was considerable variability in the disease 
progression rate (MHR: 2.5, Figure 2).
Next, we assessed how clinical factors such as age, 
year of diagnosis, Gleason grade group (</≥2), number of 
positive cores (</≥2), and PSA could explain the different 
disease progression rates in each centre. After adjustment 
for these clinical factors, the heterogeneity in risk of disease 
progression remained between the centres (Figure 2).
Discussion
When combining worldwide cohorts of men on AS, we 
noted unexplained differences in disease progression rates 
between centres (MHR: 2.5). After adjustment for various 
clinical factors (age, year of diagnosis, Gleason grade 
group, number of positive cores and PSA), substantial 
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Table 1 Overview of reasons for AS discontinuation in those centres that performed a biopsy on an annual basis (high group)
Hopkins Atlanta Lille Singapore Kagawa UCSF MDACC
Total at baseline 1,421 57 163 232 117 1441 174
Median follow-up time in years [IQR] 3.1 [1.4, 6.0] 0.8 [0.0, 2.5] 1.4 [0.9, 2.4] 2.4 [1.2, 4.0] 2.5 [1.0, 5.1] 3.2 [1.7, 5.8] 2.1 [1.1, 2.8]
Disease progression (event), % 25.1 8.4 33.4 8.1 37.9 18.0 0
Clinical progression, % 11.8 0 0 0 1.7 0.1 0
Pathological progression, % 8.3 3.9 25.9 5.6 19.8 17.3 0
Clinical and pathological progression, % 5.0 0 1.3 2.5 1.7 0 0
PSA progression (PSA-DT <3 years), % 0 4.6 2.6 0 13.8 0.6 0
Other PSA kinetics, % 0 0 0 0 0 0 0
Radiological progression, % 0 0 3.6 0 0 0 0
Other/unknown with (I) Gleason grade group 3 
or higher; (II) cT3 or higher; or (III) PSA >20, %
0.2 0 1.5 0 6.0 6.6 0
Watchful waiting/convert to active treatment/
died (competing risk), %
9.0 0 11.3 29.3 19.8 7.1 0
Data shown as 3-year cumulative incidence. AS, active surveillance.
Table 2 Overview of reasons for AS discontinuation in those centres where the follow-up biopsy was taken more than a year after AS initiation 
(intermediate group)
MSKCC Calgary Baden Cambridge Valencia MUSIC Dublin Milan-SAINT
Total at baseline 1,069 574 192 264 335 1,864 45 466
















Disease progression (event), % 3.9 16.3 17.6 6.5 24.7 6.9 0 41.8
Clinical progression, % 0.7 0 0 0 1.2 0 0 13.5
Pathological progression, % 2.9 16.3 17.6 5.6 23.1 6.4 0 10.9
Clinical and pathological progression, % 0.1 0 0 0.9 0 0 0 13.9
PSA progression (PSA-DT <3 years), % 0.2 0 0 0 0.4 0.5 0 3.4
Other PSA kinetics, % 0 0 0 0 0 0 0 0
Radiological progression, % 0 0 0 0 0 0 0 0
Other/unknown with (I) Gleason grade group 3 or 
higher; (II) cT3 or higher; or (III) PSA >20, %
16.3 0 9.7 0 1.4 25.1 39.5 1.0
Watchful waiting/convert to active  
treatment/died (competing risk), %
17.4 7.0 10.8 4.8 12.0 28.5 39.5 14.3
Data shown as 3-year cumulative incidence. AS, active surveillance.
heterogeneity in disease progression remained between 
centres.
The current European guidelines suggest that a large 
proportion of men with localized PCa do not require 
immediate radical treatment, but can be safely monitored 
using AS (10). Yet, despite the potential to monitor this 
low-risk PCa long-term with very little risk of disease 
progression (<0.03% over 15 years) (7), uptake of AS varies 
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Vancouver Helsinki Malmo Melbourne Toronto
Milan- 
PRIAS
Total at baseline 112 2,288 68 288 137 282 984 250
















Disease progression (event), % 24.9 25.1 31.4 31.3 17.9 28.0 4.4 30.2
Clinical progression, % 12.9 7.3 4.4 2.7 2.8 0.4 0 6.7
Pathological progression, % 0.9 4.1 17.6 12.7 3.0 24.2 3.2 7.3
Clinical and Pathological progression, % 5.5 5.4 1.9 6.9 3.1 0 0 12.4
PSA progression (PSA-DT <3 years), % 5.5 8.3 7.5 9.0 9.0 3.5 1.2 3.8
Other PSA kinetics, % 0 0 0 0 0 0 0 0
Radiological progression 0 0 0 0 0 0 0 0
Other/unknown with (I) Gleason grade group 3 
or higher; (II) cT3 or higher; or (III) PSA >20, %
1.9 3.1 0 0 0 0.4 9.5 0
Watchful waiting/convert to active treatment/
died (competing risk), %
5.7 11.7 7.5 8.6 2.8 4.2 11.9 8.7

















Figure 1 Univariable heterogeneity analysis, as quantified by hazard ratios (HRs), for disease progression (X-axis) and conversion to active 
treatment (Y-axis), whilst considering all other reasons for discontinuation as competing risks.
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Figure 2 Log-hazard and 95% confidence intervals (X-axis) for disease progression based on centre. The adjusted model takes into account 
age, year of diagnosis, Gleason grade group, and number of positive cores.
across countries and practices (11) and drop-out is reported 
to be as high as 38%—even where there is no evidence of 
disease progression (7). As mentioned previously, in our 
own GAP3 cohort we found that after 5 years of follow-
up, about 43% of men who started on AS discontinued (1). 
Conversion to active treatment without evidence of 
disease progression was indeed one of the main reasons 
for discontinuation (12.8%). Low acceptability of AS may 
result into overtreatment, unnecessary adverse events, and a 
higher health economic burden—hence, justifying the need 
for the development of a worldwide nomogram.
There is a need to develop a nomogram to predict 
disease progression in men suitable for AS with an optimal 
balance between sensitivity and specificity as current 
nomograms have only been found to show limited accuracy 
in predicting outcomes of these men (4). The various risk 
prediction tools available to date have shown potential, 
though all in limited settings. For example, Iremashvili 
et al. compared the probabilities of pathologically relatively 
aggressive disease using the Partin and Dinh risk tables and 
Kattan, Truong, and Kulkarni nomograms using a cohort 
of 326 PCa patients. It was found that the predictions of 
Partin and Dinh tables were not associated with biopsy 
progression, whereas the predictive value of Kattan and 
Truong nomograms was higher when compared with 
the other tools—though only for the first and second 
surveillance biopsies. The latter two nomograms were also 
able to identify low and high-risk subgroups, though the 
Kattan nomogram was found to show better correlation 
with the observed progression rate (12). Hence, using a 
large worldwide database including various centres, we 
aimed to develop a more widely applicable nomogram.
As shown in Figure 1, there was a large discrepancy 
between centres in terms of baseline hazards of disease 
progression. This is problematic when trying to develop 
a global nomogram and a better understanding of these 
observed differences is required before these can be taken 
into account in the mathematical models underlying a 
nomogram. An in-depth assessment of inclusion criteria and 
competing risks (e.g., watchful waiting, conversion to active 
treatment, or death) of the various centres is needed to 
help disentangle these baseline risks of disease progression. 
However, it is interesting to note that the relative effects 
of patient characteristics on risk of disease progression 
were fairly stable between centres (as shown in Figure 2). 
Upon adjustment for important known clinical indicators 
of disease progression, the heterogeneity between centres 
remained. These findings combined therefore indicate that 
it is possible to develop a global nomogram in future if local 
adjustments for differences in risk of disease progression 
and competing risks can be accounted for. Differences 
in disease progression rates can be incorporated by first 
collecting patient information and progression rates in a 
new centre, and subsequently using the collected data to 
update a global nomogram by re-estimating the baseline 
hazard to adjust the average predicted reclassification rate.
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As already shown in our previous publications (1,6,13-16), 
Movember’s GAP3 database provides a unique opportunity 
to assess worldwide data in the setting of AS for men with 
localised PCa. However, some limitations exist because 
not all centres could be included in our analyses due 
to the lack of information on data for discontinuation. 
Moreover, there is heterogeneity in study protocols and 
data collection across centres. Nevertheless, our findings 
show that this heterogeneity in clinical factors and follow-
up protocols does not explain the heterogeneity in risk of 
disease progression as such (Figure 2). It is therefore of 
interest to further disentangle this real-world data resource 
as it can help the development of a global nomogram. The 
next update of the GAP3 database will help address this 
next step of the development of a global nomogram as the 
database will then also contain information on imaging 
(MRI), molecular (genomics) markers, and patient-related 
outcomes.
Conclusions
Our findings of unexplained differences in baseline hazards 
for disease progression and consistent effects of clinical 
predictors between centres in the GAP3 database indicate 
that it is possible to develop a global nomogram in future. 
A next step involves the development of mathematical 
methods for local adjustments for differences in risk of 
disease progression and competing risks (e.g., watchful 
waiting, conversion to active treatment, or death) based 
on further examination of the underlying reasons for this 
heterogeneity.
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